Veloxity Labs partners with pharmaceutical, biotech and animal health companies to accelerate drug development through high-quality LC-MS/MS bioanalysis. Whether your goal is first-in-human trials, IND submission or veterinary therapeutic approval, our experienced team delivers the accurate data you need—fast.
We provide GxP-compliant, ICH M10-aligned bioanalytical services to support drug development across small and large molecules, novel modalities and biomarkers. From discovery-phase PK studies to pivotal clinical trial support, our end-to-end workflows ensure high-quality data delivered at unmatched speed—helping pharma and biotech teams make timely, confident decisions.
Veloxity Labs is a proven partner in veterinary drug development, with targeted SOPs and workflows designed for preclinical and clinical bioanalysis in companion and production animals. We helped drive industry advancement by leading the initiative that resulted in CVM’s 2024 acceptance of both ICH M10 and FDA GF#145 guidelines for animal health studies—positioning us at the forefront of veterinary bioanalysis.
In June 2024, the Center for Veterinary Medicine (CVM) began accepting ICH M10 guidance for animal health study design—a major step forward for the industry, led in part by Veloxity Labs’ Director of Quality Assurance, Chris Tudan, PhD. Download our report to explore how this change came about, the challenges it addresses and what it means for the future of regulatory bioanalysis in animal health.
